<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003748</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066868</org_study_id>
    <secondary_id>P30CA016042</secondary_id>
    <secondary_id>UCLA-HSPC-9703008</secondary_id>
    <secondary_id>P-UPHJOHN-6475-96014</secondary_id>
    <secondary_id>NCI-G99-1497</secondary_id>
    <nct_id>NCT00003748</nct_id>
  </id_info>
  <brief_title>Irinotecan in Treating Patients With Esophageal or Stomach Cancer</brief_title>
  <official_title>Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmacia and Upjohn</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die.

      PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who
      have esophageal or stomach cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the antitumor activity of irinotecan in patients with adenocarcinoma
      of the esophagus or gastric cardia. II. Evaluate the toxicities of this drug in this patient
      population.

      OUTLINE: This is a multicenter study. Patients receive irinotecan intravenous (IV) over 90
      minutes once a week for 4 weeks followed by a 2 week rest period. Treatment continues in the
      absence of unacceptable toxicity or disease progression. Patients are followed every 3 months
      until death.

      PROJECTED ACCRUAL: A total of 18-32 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1998</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">June 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the antitumor activity of irinotecan hydrochloride (CPT-11) in patients with unresectable adenocarcinoma of the esophagus and gastric cardia who have failed prior chemotherapy</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the toxicities of irinotecan hydrochloride (CPT-11) in the patient population</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>irinotecan hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.</description>
    <arm_group_label>irinotecan hydrochloride</arm_group_label>
    <other_name>CPT-11</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be &gt; 18 years of age

          -  Patients must have a performance status of 0-2 on the Eastern Cooperative Oncology
             Group (ECOG) Performance Scale

          -  Patients must have a predicted life expectancy of at least 12 weeks

          -  Patients must have a pretreatment granulocyte count of &gt;1500/mm3, a hemoglobin level
             of &gt;9.0 gm/dL and the platelet count of &gt;100000/mm3

          -  Patients must have adequate renal function as documented by a serum creatinine &lt; 2.0
             mg/dL

          -  Patients must have adequate hepatic function as documented by a serum bilirubin &lt; 1.5
             mg/dL, regardless of whether patients have liver involvement secondary to tumor.
             Aspartate transaminase must be &lt; 3 x institutional upper limit of normal unless the
             liver is involved with tumor, in which case the aspartate transaminase must be &lt; 5 x
             institutional upper limit of normal

          -  Patients must have histologically proven adenocarcinoma of the esophagus or gastric
             cardia with progression despite prior chemotherapy

          -  Patients must have disease radiologically measurable bidimensionally

          -  Patients must have an interval of 4 weeks from prior chemotherapy, immunotherapy, or
             radiation therapy

        Exclusion Criteria:

          -  Patients with any active or uncontrolled infection

          -  Patients with psychiatric disorders that would interfere with consent or follow-up

          -  Patients with a history of myocardial infarction within the previous six months or
             congestive heart failure requiring therapy

          -  Patients with a history of prior malignancy except for adequately treated basal cell
             or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the
             patient has been disease-free for at least five years

          -  Pregnant or lactating women. Men and women of reproductive potential may not
             participate unless they have agreed to use an effective contraceptive method

          -  Presence of clinically apparent central nervous system metastases or carcinomatous
             meningitis

          -  Patients with uncontrolled diabetes mellitus

          -  Patients with any other severe concurrent disease which, in the judgment of the
             investigator, would make the patient inappropriate for entry into this study

          -  Prior therapy with a deoxyribonucleic acid (DNA) topoisomerase inhibitor

          -  Patients with known Gilbert's syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel R. Hecht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Jude Heritage Health Foundation</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Freeman Memorial Hospital</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA - Antelope Valley Cancer Center</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Eddie Hu, M.D.</name>
      <address>
        <city>Monterey Park</city>
        <state>California</state>
        <zip>91754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital of the Monterey Peninsula</name>
      <address>
        <city>Monterey</city>
        <state>California</state>
        <zip>93940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Jerome L. Rubin</name>
      <address>
        <city>Monterey</city>
        <state>California</state>
        <zip>93940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura County Hematology-Oncology Medical Group, Inc.</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilshire Oncology Medical Center</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salinas Valley Memorial Hospital</name>
      <address>
        <city>Salinas</city>
        <state>California</state>
        <zip>93901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Santa Barbara</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sansum Medical Clinic</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James L. Poth, M.D., Michael Alexander, M.D., Inc.</name>
      <address>
        <city>Santa Cruz</city>
        <state>California</state>
        <zip>95065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marian Medical Center</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Marilou Terpenning</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Robert C. Klein</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dominican and Watsonville Community Hospital</name>
      <address>
        <city>Soquel</city>
        <state>California</state>
        <zip>95073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Robles Regional Medical Center</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Associates Medical Group</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Cancer Center - Santa Clarita</name>
      <address>
        <city>Valencia</city>
        <state>California</state>
        <zip>91355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Medical Center of North County</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Hematology and Oncology</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <zip>91307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Consultants</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2004</study_first_posted>
  <last_update_submitted>October 28, 2015</last_update_submitted>
  <last_update_submitted_qc>October 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I gastric cancer</keyword>
  <keyword>stage II gastric cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage I esophageal cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

